Skip to main navigation
Axsome Corporate Homepage
  • About Axsome
    • All
    • Overview
    • Management Team
    • Board of Directors
    • Intellectual Property
    • State Disclosures
  • Portfolio
    • All
    • Overview
    • Products Overview  down arrow
      • All
      • Overview
      • Auvelity® (dextromethorphan-bupropion)
      • Sunosi® (solriamfetol)
      • Symbravo® (meloxicam and rizatriptan)
    • Pipeline Overview  down arrow
      • All
      • Overview
      • AXS-05
      • AXS-12
      • AXS-14
  • Conditions
    • All
    • Overview
    • Depression
    • Migraine
    • Alzheimer’s Disease Agitation
    • Excessive Daytime Sleepiness
    • Narcolepsy
    • Fibromyalgia
    • Smoking Cessation
  • Axsome Corporate Homepage
  • Science
    • All
    • Overview
    • Medical Information U.S.
    • Medical Information Canada
    • Publications
  • Investors
    • All
    • Overview
    • Corporate Governance
    • Stock Information
    • Financial Information
    • News & Events
    • Webcasts & Presentations
    • Analyst Coverage
    • Shareholder Services
  • Careers
    • All
    • Overview
    • Current Opportunities

Investor
Relations

Investors

Investors

Minimum 15 minutes delayed. Source: LSEG

Featured Events
August 10, 2026 at 8:00 AM EDT
Axsome Second Quarter 2026 Financial Results
Click here for Webcast
May 01, 2026 at 8:00 AM EDT
AUVELITY in Agitation Associated with Dementia due to Alzheimer’s Disease FDA Approval Call
Click here for Webcast
See all Events
Recent News

August 31, 2026

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

Click here to read more

August 10, 2026

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Click here to read more

July 15, 2026

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Click here to read more
See all News

Email Alerts

Click here to subscribe to Axsome Therapeutics email alerts.

Subscribe here

  • About Axsome
    • All
    • Overview
    • Management Team
    • Board of Directors
    • Intellectual Property
    • State Disclosures
  • Portfolio
    • All
    • Products Overview
    • Products Overview
    • Auvelity™ (dextromethorphan-bupropion)
    • Sunosi® (solriamfetol)
    • Symbravo® (meloxicam and rizatriptan)
    • Pipeline Overview
    • AXS‑05
    • AXS‑12
    • AXS‑14
  • Conditions
    • All
    • Overview
    • Depression
    • Migraine
    • Alzheimer's
      Disease Agitation
    • Excessive Daytime
      Sleepiness
    • Narcolepsy
    • Fibromyalgia
    • Smoking Cessation
  • Science
    • All
    • Overview
    • Medical Information U.S.
    • Medical Information International
    • Publications
  • Investors
    • All
    • Overview
    • Corporate Governance
    • Stock Information
    • Financial Information
    • News & Events
    • Webcasts &
      Presentations
    • Analyst Coverage
    • Shareholder Services
  • Careers
    • All
    • Careers
    • Current Opportunities
Axsome
  • Contact Us
  • Privacy Notice
  • Terms of Use
  • See Axsome Therapeutics on LinkedIn

AXSOME and its logos are trademarks or registered trademarks of Axsome Therapeutics,Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2026 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, New York, NY, 10007 info@axsome.com